Chiesi bets $160M on Gossamer Bio’s make-or-break late-stage PAH drug

Gos­samer Bio has lined up a part­ner to foot the de­vel­op­ment and com­mer­cial­iza­tion bill for its make-or-break late-stage drug, ex­pand­ing Phase 3 plans and paving the way for its launch out­side the US.

Ital­ian phar­ma Chiesi will pay Gos­samer $160 mil­lion to kick off the col­lab­o­ra­tion. In ad­di­tion to that ini­tial pay­ment — dubbed a “de­vel­op­ment re­im­burse­ment” — Chiesi will al­so split fu­ture costs for the can­di­date, ser­a­lu­tinib, and com­mit a to­tal of $226 mil­lion in reg­u­la­to­ry and sales mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.